0

What's New in Atopic Dermatitis

Yael Renert-Yuval, Emma Guttman-Yassky

Dermatol Clin. 2019 Apr;37(2):205-213.

PMID: 30850043

Abstract:

The evolving discoveries in atopic dermatitis (AD) shed light on disease pathogenesis and allow better management of patients. Dupiluamab was the first targeted agent approved for AD, proving for the first time AD can be treated with a single cytokine antagonism. Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP906673243 Crisaborole Crisaborole 906673-24-3 Price
qrcode